Rakuten Securities Inc. Buys Shares of 3,918 Royalty Pharma plc (NASDAQ:RPRX)

Rakuten Securities Inc. bought a new stake in Royalty Pharma plc (NASDAQ:RPRXFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,918 shares of the biopharmaceutical company’s stock, valued at approximately $110,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RPRX. Allworth Financial LP grew its stake in Royalty Pharma by 89.8% in the third quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 451 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Royalty Pharma by 112.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 531 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of Royalty Pharma by 210.8% in the second quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 546 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Royalty Pharma in the first quarter worth about $113,000. Finally, CWM LLC lifted its position in shares of Royalty Pharma by 75.9% in the third quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 2,064 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $27.61 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 7.90 and a quick ratio of 7.90. The stock has a fifty day moving average price of $29.81 and a two-hundred day moving average price of $28.50. Royalty Pharma plc has a 52-week low of $25.92 and a 52-week high of $36.67. The firm has a market capitalization of $16.50 billion, a P/E ratio of 14.61, a P/E/G ratio of 0.78 and a beta of 0.45.

Royalty Pharma (NASDAQ:RPRXGet Free Report) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.12. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. The firm had revenue of $736.00 million during the quarter, compared to analyst estimates of $702.90 million. As a group, analysts anticipate that Royalty Pharma plc will post 3.95 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 17th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $0.84 annualized dividend and a yield of 3.04%. Royalty Pharma’s dividend payout ratio is currently 44.44%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Bank of America cut their price objective on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, April 12th. JPMorgan Chase & Co. cut their price objective on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday, February 20th. The Goldman Sachs Group reduced their price objective on Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Finally, StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $46.75.

Get Our Latest Stock Analysis on Royalty Pharma

Royalty Pharma Profile

(Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

See Also

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma plc (NASDAQ:RPRXFree Report).

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.